Literature DB >> 30767032

[Patients with metastatic spinal cord compression profit from rapid multidisciplinary diagnostics and treatment].

Carsten Nieder1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 30767032     DOI： 10.1007/s00066-019-01437-6

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  4 in total

Review 1.  Assessment and Management of Patients With Metastatic Spinal Cord Compression: A Multidisciplinary Review.

Authors:  Andrew J Lawton; Kathleen A Lee; Andrea L Cheville; Marco L Ferrone; Dirk Rades; Tracy A Balboni; Janet L Abrahm
Journal:  J Clin Oncol       Date:  2018-11-05       Impact factor: 44.544

2.  Radiotherapy With 4 Gy × 5 Versus 3 Gy × 10 for Metastatic Epidural Spinal Cord Compression: Final Results of the SCORE-2 Trial (ARO 2009/01).

Authors:  Dirk Rades; Barbara Šegedin; Antonio J Conde-Moreno; Raquel Garcia; Ana Perpar; Michaela Metz; Harun Badakhshi; Andreas Schreiber; Mirko Nitsche; Peter Hipp; Wolfgang Schulze; Irenaeus A Adamietz; Darius Norkus; Volker Rudat; Jon Cacicedo; Steven E Schild
Journal:  J Clin Oncol       Date:  2016-01-04       Impact factor: 44.544

3.  (ICORG 05-03): prospective randomized non-inferiority phase III trial comparing two radiation schedules in malignant spinal cord compression (not proceeding with surgical decompression); the quality of life analysis.

Authors:  K A Lee; M Dunne; C Small; P J Kelly; O McArdle; J O'Sullivan; D Hacking; M Pomeroy; J Armstrong; M Moriarty; A Clayton-Lea; I Parker; C D Collins; P Thirion
Journal:  Acta Oncol       Date:  2018-02-08       Impact factor: 4.089

Review 4.  An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report.

Authors:  Daniel E Spratt; Whitney H Beeler; Fabio Y de Moraes; Laurence D Rhines; Joseph J Gemmete; Neeraj Chaudhary; David B Shultz; Sean R Smith; Alejandro Berlin; Max Dahele; Ben J Slotman; Kelly C Younge; Mark Bilsky; Paul Park; Nicholas J Szerlip
Journal:  Lancet Oncol       Date:  2017-12       Impact factor: 41.316
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.